Avalo Therapeutics (AVTX) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.83

Estimate

-$0.62

Surprise

-33.2%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Avalo Therapeutics (AVTX) reported a wider loss than forecast — diluted EPS of -$0.83 against the -$0.62 estimate (a 33.2% shortfall).

TrendMatrix currently rates AVTX Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -33.2% surprise compares with a +3.2% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$17.45

Price target

$38.35

Stop

$15.42

Upside to target

+119.8%

Reward-to-risk

10.7:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$861.8M

P/E (fwd)

-5.9

52-week range

$9.84–$24.27

Off 52-week high

28.1%

RSI (14)

23

Volume vs avg

1.54×

Score today

5.3/10